Brad Robling
Directeur/Bestuurslid bij Auron Therapeutics, Inc.
Profiel
Brad Robling is currently a Director at Auron Therapeutics, Inc. He previously worked as a Director-Investor Relations at Eli Lilly & Co.
Actieve functies van Brad Robling
| Bedrijven | Functie | Begin |
|---|---|---|
Auron Therapeutics, Inc.
 Auron Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Auron Therapeutics, Inc. operates as a biotechnology company. It aims to cure cancer by radically changing the paradigm of cancer therapeutics from cell killing to transformation of malignant cells into more normal functioning cells. The company was founded by Kate Yen, Matt Vander Heiden, Ross Levine, and Eytan Stein and is headquartered in Wellesley, MA. | Directeur/Bestuurslid | - |
Eerdere bekende functies van Brad Robling
| Bedrijven | Functie | Einde |
|---|---|---|
| ELI LILLY AND COMPANY | Public Communications Contact | - |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| ELI LILLY AND COMPANY | Health Technology |
| Bedrijven in privébezit | 1 |
|---|---|
Auron Therapeutics, Inc.
Auron Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Auron Therapeutics, Inc. operates as a biotechnology company. It aims to cure cancer by radically changing the paradigm of cancer therapeutics from cell killing to transformation of malignant cells into more normal functioning cells. The company was founded by Kate Yen, Matt Vander Heiden, Ross Levine, and Eytan Stein and is headquartered in Wellesley, MA. | Commercial Services |
